カテゴリ： Allied Market Research, 世界, 医療/バイオ

肺動脈性肺高血圧症（PAH）治療のグローバル市場（2021〜2031）：エンドセリン受容体拮抗薬（ERA）、PDE-5阻害剤、プロスタサイクリン・プロスタサイクリン類似体、SGC刺激薬

■ 英語タイトル：Pulmonary Arterial Hypertension Treatment Market By by Drug Type (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB173）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB173
■ 発行日：2022年11月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：335
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[肺動脈性肺高血圧症（PAH）治療のグローバル市場（2021〜2031）：エンドセリン受容体拮抗薬（ERA）、PDE-5阻害剤、プロスタサイクリン・プロスタサイクリン類似体、SGC刺激薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に7,177.81百万ドルであった世界の肺動脈性肺高血圧症（PAH）治療市場規模が、2031年までに11,968.60百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）5.2%で成長すると予測しています。本レポートは、肺動脈性肺高血圧症（PAH）治療の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、治療薬別（エンドセリン受容体拮抗薬（ERA）、PDE-5阻害剤、プロスタサイクリン・プロスタサイクリン類似体、SGC刺激薬）分析、種類別（ブランド、ジェネリック）分析、投与経路別（経口、静脈内/皮下、吸入）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、United Therapeutics Corporation、Bayer AG、Gilead Sciences, Inc.、Johnson & Johnson、Viatris Inc.、GlaxoSmithKline、Novartis、Lupin Pharmaceuticals, Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の肺動脈性肺高血圧症（PAH）治療市場規模：治療薬別
- エンドセリン受容体拮抗薬（ERA）の市場規模
- PDE-5阻害剤の市場規模
- プロスタサイクリン・プロスタサイクリン類似体の市場規模
- SGC刺激薬の市場規模
・世界の肺動脈性肺高血圧症（PAH）治療市場規模：種類別
- ブランド治療薬における市場規模
- ジェネリック治療薬における市場規模
・世界の肺動脈性肺高血圧症（PAH）治療市場規模：投与経路別
- 経口投与における市場規模
- 静脈内/皮下投与における市場規模
- 吸入投与における市場規模
・世界の肺動脈性肺高血圧症（PAH）治療市場規模：地域別
- 北米の肺動脈性肺高血圧症（PAH）治療市場規模
- ヨーロッパの肺動脈性肺高血圧症（PAH）治療市場規模
- アジア太平洋の肺動脈性肺高血圧症（PAH）治療市場規模
- 中南米・中東・アフリカの肺動脈性肺高血圧症（PAH）治療市場規模
・企業状況
・企業情報

世界の肺動脈性肺高血圧症（PAH）治療市場は、2021年には71億7,781万ドルと評価され、2022年から2031年までの年平均成長率は5.2%を記録し、2031年には119億6,860万ドルに達すると予測されています。

肺動脈性肺高血圧症（PAH）は、内皮機能障害と血管リモデリングが微小な肺動脈を閉塞させ、肺血管抵抗と肺圧を上昇させ、その結果、心拍出量が減少し、右心不全に陥り、最終的に患者が死亡する病態と定義されています。肺動脈感染症は、結合組織病、HIV感染、門脈圧亢進症（肝臓病）、鎌状赤血球症、先天性心疾患など、代々受け継がれる病態を含む多くの病態が原因で発生する可能性があります。肺動脈性肺高血圧症に関連する症状は、唇や皮膚が青くなる（チアノーゼ）、胸の圧迫感や痛み、めまい、倦怠感、運動中や安静時の息切れ（呼吸困難）などです。肺動脈性肺高血圧症患者の治療には、シルデナフィル（レバチオ、バイアグラ）やタダラフィル（アドシルカ）などの薬剤が使用されます。

肺動脈性肺高血圧症（PAH）治療市場の成長を促進する主な要因は、肺動脈性肺高血圧症に罹患する高齢者人口の有病率の増加、HIV患者の有病率の増加、医療費の急増が市場の成長を後押ししています。2020年の国立生物工学情報センターによると、HIV陽性患者はHIV陰性患者よりも肺動脈性肺高血圧症（PAH）の有病率が0.5％高く、その差は約2500倍であることが報告されています。
また、2020年に発行されたCardiovascular Diagnosis and Therapy Journal誌の論文（サハラ以南のアフリカや低・中所得国を中心に肺高血圧症の世界的な疫学を論じた論文）のデータによると、先天性心疾患、リウマチ性心疾患、HIVのリスクが高い65歳以下の肺高血圧症患者の80％が低・中所得国に居住していると推定されています。

さらに、肺動脈性肺高血圧症の効果的な治療のための製品承認数の増加や規制当局による主要な戦略的開発が市場成長に寄与しています。例えば、Johnson & JohnsonのJanssen Pharmaceutical Companiesは、肺動脈性肺高血圧症（PAH）治療薬の製造・開発に携わる主要企業の1つです。同社は、肺動脈性肺高血圧症の患者を治療するためにUPTRAVI製品を静脈内投与するための製品承認申請をFDAに提出したことを発表しました。しかし、薬剤ベースの肺動脈性肺高血圧症（PAH）治療に伴う副作用が、予測期間中の市場成長を制限しています。さらに、発展途上国における成長の可能性の高まりは、肺動脈性肺高血圧症（PAH）治療市場で事業を展開する市場プレーヤーに有利な機会を提供します。

肺動脈性肺高血圧症（PAH）治療薬市場は、薬剤タイプ、種類、投与経路、地域に区分されます。薬剤タイプ別では、エンドセリン受容体拮抗薬（ERA）、PDE-5阻害薬、プロスタサイクリン、プロスタサイクリン類似体＆sGC刺激薬に分類されます。種類別では、さらにブランド品とジェネリック医薬品に二分されます。ブランド品セグメントはさらに、小売薬局、病院薬局、オンライン薬局に細分化され、ジェネリック医薬品は、さらに小売薬局、病院薬局、オンライン薬局に細分化されます。投与経路別では、経口、静脈内/皮下、吸入に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

世界の肺動脈性肺高血圧症（PAH）治療薬市場で事業を展開している主要企業には、Bayer AG、GlaxoSmithKline Plc、Gilead Sciences, Inc.、Johnson & Johnson、Lupin Pharmaceuticals, Inc.、Sandoz Inc.（Novartis）、Sun Pharmaceutical Industries, Ltd.、Teva Pharmaceutical Industries Ltd.、United Therapeutics Corporation、Viatris Inc.などがあります。

ステークホルダーにとっての主なメリット
・肺動脈性肺高血圧症（PAH）治療薬の市場機会を特定するため、2021年から2031年までの市場セグメント、現在の動向、予測、市場ダイナミクスを定量的に分析します。
・肺動脈性肺高血圧症（PAH）治療薬の市場機会を特定するために、2021年から2031年までの市場分析および市場ダイナミクスを提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・肺動脈性肺高血圧症（PAH）治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・肺動脈性肺高血圧症（PAH）治療の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
薬剤タイプ別
エンドセリン受容体拮抗薬（ERAs）
PDE-5阻害薬
プロスタサイクリン＆プロスタサイクリン類似物質
SGC刺激薬

種類別
ブランド医薬品
ジェネリック医薬品

投与経路別
経口
静脈内/皮下
吸入

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
United Therapeutics Corporation
Bayer AG
Gilead Sciences, Inc.
Johnson & Johnson
Viatris Inc.
GlaxoSmithKline
Novartis
Lupin Pharmaceuticals, Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Endothelin Receptor Antagonists (ERAs)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 PDE-5 Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Prostacyclin and Prostacyclin Analogs
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 SGC Stimulators
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Branded
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
5.2.4.1 Retail Pharmacy Market size and forecast, by region
5.2.4.2 Hospital Pharmacy Market size and forecast, by region
5.2.4.3 Online Pharmacy Market size and forecast, by region
5.3 Generics
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
5.3.4.1 Retail Pharmacy Market size and forecast, by region
5.3.4.2 Hospital Pharmacy Market size and forecast, by region
5.3.4.3 Online Pharmacy Market size and forecast, by region
CHAPTER 6: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Intravenous/ subcutaneous
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Inhalational
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by by Drug Type
7.2.3 North America Market size and forecast, by Type
7.2.3.1 North America Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.2.3.2 North America Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by by Drug Type
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by by Drug Type
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by by Drug Type
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by by Drug Type
7.3.3 Europe Market size and forecast, by Type
7.3.3.1 Europe Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.3.3.2 Europe Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by by Drug Type
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by by Drug Type
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by by Drug Type
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by by Drug Type
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by by Drug Type
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by by Drug Type
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by by Drug Type
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.3.1 Asia-Pacific Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.4.3.2 Asia-Pacific Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by by Drug Type
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by by Drug Type
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by by Drug Type
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by by Drug Type
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by by Drug Type
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by by Drug Type
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by by Drug Type
7.5.3 LAMEA Market size and forecast, by Type
7.5.3.1 LAMEA Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.5.3.2 LAMEA Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by by Drug Type
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by by Drug Type
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by by Drug Type
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by by Drug Type
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 United Therapeutics Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bayer AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Viatris Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 GlaxoSmithKline
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Lupin Pharmaceuticals, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sun Pharmaceutical Industries, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 2. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), BY REGION, 2021-2031 ($MILLION)
TABLE 3. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR PDE-5 INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR PDE-5 INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR PROSTACYCLIN AND PROSTACYCLIN ANALOGS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR PROSTACYCLIN AND PROSTACYCLIN ANALOGS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR SGC STIMULATORS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR SGC STIMULATORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 11. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR BRANDED, BY REGION, 2021-2031 ($MILLION)
TABLE 12. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR BRANDED, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 14. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 15. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 16. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 17. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR GENERICS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR GENERICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 21. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 22. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 24. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR INTRAVENOUS/ SUBCUTANEOUS, BY REGION, 2021-2031 ($MILLION)
TABLE 27. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR INTRAVENOUS/ SUBCUTANEOUS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR INHALATIONAL, BY REGION, 2021-2031 ($MILLION)
TABLE 29. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR INHALATIONAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 35. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 36. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 38. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 39. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 41. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 43. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 44. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 47. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. EUROPE GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 51. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 53. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 55. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 56. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 58. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 59. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 61. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 62. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 64. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 65. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 67. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 68. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. ASIA-PACIFIC BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. ASIA-PACIFIC GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 76. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 77. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 79. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 80. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 82. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 83. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 85. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 86. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 88. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 89. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 94. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 95. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 96. LAMEA BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 97. LAMEA GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 99. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 100. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 101. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 102. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 103. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 104. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 105. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 106. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 107. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 108. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 109. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 110. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 111. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 112.UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT
TABLE 113.UNITED THERAPEUTICS CORPORATION: OPERATING SEGMENTS
TABLE 114.UNITED THERAPEUTICS CORPORATION: PRODUCT PORTFOLIO
TABLE 115.UNITED THERAPEUTICS CORPORATION: NET SALES,
TABLE 116.UNITED THERAPEUTICS CORPORATION: KEY STRATERGIES
TABLE 117.BAYER AG: COMPANY SNAPSHOT
TABLE 118.BAYER AG: OPERATING SEGMENTS
TABLE 119.BAYER AG: PRODUCT PORTFOLIO
TABLE 120.BAYER AG: NET SALES,
TABLE 121.BAYER AG: KEY STRATERGIES
TABLE 122.GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 123.GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 124.GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 125.GILEAD SCIENCES, INC.: NET SALES,
TABLE 126.GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 127.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 128.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 129.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 130.JOHNSON & JOHNSON: NET SALES,
TABLE 131.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 132.VIATRIS INC.: COMPANY SNAPSHOT
TABLE 133.VIATRIS INC.: OPERATING SEGMENTS
TABLE 134.VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 135.VIATRIS INC.: NET SALES,
TABLE 136.VIATRIS INC.: KEY STRATERGIES
TABLE 137.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 138.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 139.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 140.GLAXOSMITHKLINE: NET SALES,
TABLE 141.GLAXOSMITHKLINE: KEY STRATERGIES
TABLE 142.NOVARTIS: COMPANY SNAPSHOT
TABLE 143.NOVARTIS: OPERATING SEGMENTS
TABLE 144.NOVARTIS: PRODUCT PORTFOLIO
TABLE 145.NOVARTIS: NET SALES,
TABLE 146.NOVARTIS: KEY STRATERGIES
TABLE 147.LUPIN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 148.LUPIN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 149.LUPIN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 150.LUPIN PHARMACEUTICALS, INC.: NET SALES,
TABLE 151.LUPIN PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 152.SUN PHARMACEUTICAL INDUSTRIES, INC.: COMPANY SNAPSHOT
TABLE 153.SUN PHARMACEUTICAL INDUSTRIES, INC.: OPERATING SEGMENTS
TABLE 154.SUN PHARMACEUTICAL INDUSTRIES, INC.: PRODUCT PORTFOLIO
TABLE 155.SUN PHARMACEUTICAL INDUSTRIES, INC.: NET SALES,
TABLE 156.SUN PHARMACEUTICAL INDUSTRIES, INC.: KEY STRATERGIES
TABLE 157.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 158.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 159.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 160.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 161.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 肺動脈性肺高血圧症（PAH）のグローバル市場2023～2033：プロスタサイクリン＆プロスタサイクリン類似体、エンドセリン受容体拮抗薬（ERA）、ホスホジエステラーゼ-5（PDE-5）阻害薬、可溶性グアニル酸シクラーゼ（sGC）刺激薬
  • 肺動脈性肺高血圧症（PAH）治療薬のグローバル市場：エンドセリン受容体拮抗薬（ERAs)、血管拡張薬、ホスホジエステラーゼ-5(PDE-5)阻害剤、可溶性グアニル酸シクラーゼ（sGC）刺激剤、その他
  • 胃がん のグローバル市場（2021-2031）：腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB173 )"肺動脈性肺高血圧症（PAH）治療のグローバル市場（2021〜2031）：エンドセリン受容体拮抗薬（ERA）、PDE-5阻害剤、プロスタサイクリン・プロスタサイクリン類似体、SGC刺激薬" (英文：Pulmonary Arterial Hypertension Treatment Market By by Drug Type (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。